Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
about
Atezolizumab for the treatment of non-small cell lung cancer.The role of an immune checkpoint score in resected non-small cell lung cancer patients' prognosis.Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer.Eosinophils: The unsung heroes in cancer?Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.Trial watch: Immune checkpoint blockers for cancer therapy.PD-1/PD-L1 Axis in Lung Cancer.Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?Atezolizumab in advanced non-small cell lung cancer.Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.PD-L1 expression testing in non-small cell lung cancer.Immunotherapy in treatment naïve advanced non-small cell lung cancer.Effectiveness of anti-PD-1/PD-L1 antibodies in urothelial carcinoma patients with different PD-L1 expression levels: a meta-analysis.Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis.Immunotherapy in previously treated non-small cell lung cancer (NSCLC).Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.Immunotherapy in the Asiatic population: any differences from Caucasian population?Do immune checkpoint inhibitors need new studies methodology?Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung CancerAtezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future ProspectsDurvalumab in NSCLC: latest evidence and clinical potentialPROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectivesComparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trialsAnti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
P2860
Q38675969-F99A7218-B067-4D35-89B1-4D90F4C0A2D6Q47134599-9A0857CD-5F6F-4737-AC57-8D78FCAD87EBQ47148072-51E08D09-69B4-459B-976D-2478DE8008EEQ47225787-D7E4293B-5B41-4C72-BE6D-35670A910982Q47277879-D0FC3070-C775-4614-A107-5B59D7242CFFQ47304240-7B9C90D1-C1F2-4A85-9F09-8A6B49476055Q47393365-97FF467A-9363-4DF5-A3F3-12EE2D251E7AQ47717168-0B519915-1D9D-4324-88EE-D698FD7A436DQ47821832-93A578BB-763B-4C90-A94D-A3FF8AAC4B64Q49259266-9DFF56B8-DC06-4FB4-A039-0F83E1290035Q49434203-1F4462E4-4618-4798-B486-E0A8B5B263BBQ50070316-5A42DDFC-4240-491C-9F84-B381837243A7Q52584388-0FB8D25E-5C54-4FC4-A960-ED098B87EE8BQ52624361-886C98E2-28EC-42B9-86C1-657573CB0298Q52649584-4476539E-E49C-487A-BE48-711496B2C1AFQ52661373-CB5FC0E8-23EC-404D-A838-C3F1B9A91C81Q52723409-00887ED0-393A-41EE-96E3-7D0D1E905A27Q55284597-7516192E-183F-40A0-B745-C3CA18387CF5Q55311366-F03A3C0C-9AC8-4361-BB5E-7ADCBF3CD9A4Q55312983-0C16538F-57E2-4668-9B57-7DDB1BD5963EQ55375458-DAFC6386-DD1D-4E1E-80A4-64F8A7788ADFQ55401509-7594DF7F-4FA2-48AE-BF48-9BBCEC4DFD92Q55717841-A5E1033B-34F5-434A-B3DB-264271F845ADQ57174372-B0363B0D-EEDE-4D88-B666-FA11D8BB2F47Q57174881-56843011-9CF7-4546-8C40-12680B0EC907Q57816055-3F9D17A1-C7CF-4381-95EE-72839EF09F4BQ58562303-B57D90D1-B674-46DC-993E-81B1357AF3CEQ58562314-DDF23228-82E7-4869-9F6D-F88676498527Q58699431-0277A475-5F4B-4E71-898D-5216BA1DA208Q58754581-B202CE25-D012-4924-B2C1-683E0C09C957Q58768522-1E1D1B2B-614B-4C70-8968-1458563F6241Q58795231-81F2B822-2BC9-4B73-8AA0-F7885D7154D7
P2860
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@ast
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@en
type
label
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@ast
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@en
prefLabel
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@ast
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@en
P2093
P2860
P50
P921
P356
P1476
Phase II Trial of Atezolizumab ...... mall-Cell Lung Cancer (BIRCH).
@en
P2093
Alan Sandler
Chee Keong Toh
Daniel Christoph
Enric Carcereny Costa
Frances A Shepherd
Geetha Shankar
Jamie E Chaft
Jeffrey Rothenstein
Jiaheng Qiu
P2860
P304
JCO2016719476
P356
10.1200/JCO.2016.71.9476
P407
P577
2017-06-13T00:00:00Z